The observation that niclosamide can target the Wnt, mTOR and STAT3 pathways and reverse platinum resistance, provides compelling evidence to consider clinical studies with niclosamide in patients with ovarian cancer. This evidence concerns the gene STAT3 and ovarian carcinoma.